Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance

18 Nov 2021

Abstract excerpt

Lenvatinib is the first target drug approved for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the mechanisms of lenvatinib resistance and resistant targets in HCC are poorly understood. By using CRISPR/Cas9 library screening, we screened out two key resistance genes, neurofibromin 1(NF1), and dual specificity phosphatase 9 (DUSP9), as critical drivers for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Cancer Mechanisms and Therapy
Share to FOXO transcription factor regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34795217
DOI: 10.1038/s41420-021-00747-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistancePMID 34795217Read ↗

Genome-wide CRISPR Screening Identifies NFκB and c-MET as Druggable Targets to Sensitize Lenvatinib Treatment in Hepatocellular CarcinomaSemantic proximity Read ↗

CRISPR/Cas9 screening reveals that ASB2 inhibits p53-dependent ferroptosis to mediates Lenvatinib resistance in hepatocellular carcinomaSemantic proximity Read ↗

Systematic decoding of the resistance mechanisms and therapeutic vulnerabilities in TKI-resistant hepatocellular carcinomaSemantic proximity Read ↗

Long Noncoding RNA XIST Promotes Resistance to Lenvatinib in Hepatocellular Carcinoma Cells via Epigenetic Inhibition of NOD2Semantic proximity Read ↗

Combination therapy for HCC: from CRISPR screening to the design of clinical therapiesSemantic proximity Read ↗

Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR LibrariesSemantic proximity Read ↗

Ring Finger Protein 141 (RNF141) Mediates Resistance to Sorafenib in Hepatocellular Carcinoma and Its MechanismsSemantic proximity Read ↗

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.Semantic proximity Read ↗

Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1Semantic proximity Read ↗

Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling AxisSemantic proximity Read ↗

Identification of driver genes and target drugs-related genes in liver cancer based on targeted next generation sequencing.Semantic proximity Read ↗

Mechanisms of tumor heterogeneity in TACE-resistant liver cancer: Insights from single-cell and whole-exome sequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.